Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT-Reference-Cited by-同舟云学术

Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT

Published:2024-08-27 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Novak Urban,Mooyaart Jarl E.,Daskalakis Michael^ORCID,Scheid Christof,Gabellier Ludovic,Yakoub-Agha Ibrahim,Ram Ron^ORCID,Forcade Edouard,López-Corral Lucía,Nicholson Emma^ORCID,Galli Eugenio^ORCID,Stölzel Friedrich^ORCID,Bethge Wolfgang^ORCID,Wagner-Drouet Eva Maria^ORCID,Hoogenboom Jorinde D.,Mielke Stephan,Arber Caroline^ORCID,Simonetta Federico^ORCID,Chabannon Christian^ORCID,Kuball Jürgen^ORCID,Ruggeri Annalisa,Malard Florent^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02401-4.pdf

Reference11 articles.

1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. https://doi.org/10.1056/NEJMoa1804980.

2. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44. https://doi.org/10.1056/NEJMoa1707447.

3. Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36:7505. https://doi.org/10.1200/JCO.2018.36.15_suppl.7505. 15_suppl

4. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet (Lond, Engl). 2022;399:2294–308. https://doi.org/10.1016/s0140-6736(22)00662-6

5. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54. https://doi.org/10.1056/NEJMoa2116133.